Stallimycin
Also known as: Aziminomycin, Distamycin, Distamycin A, NSC-308847, Stallimycin
Source Stallimycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Stallimycin (distamycin A) is a naturally occurring oligopeptide antibiotic produced by Streptomyces distallicus. It binds non-covalently to the minor groove of B-form DNA at AT-rich regions, inhibiting RNA and DNA synthesis. It has demonstrated antiviral, antibacterial, and antitumor activities in vitro and in vivo, but has not progressed to clinical approval due to toxicity concerns. It served as the parent scaffold for numerous synthetic analogues (lexitropsins, tallimustine) developed in cancer and antiviral research.
Mechanism of Action
Binds to the minor groove of double-stranded DNA at AT-rich sequences, inhibiting DNA-directed RNA synthesis and DNA replication by physically blocking transcription and replication machinery.
Routes of Administration
Goals & Uses
- Antitumor activityOncologyLow
- Antiviral activityInfectious DiseaseLow
- Research tool for DNA-binding studiesBiochemical ResearchHigh
- Antibacterial activityInfectious DiseaseLow
Contraindications
- Known hypersensitivity to distamycin or related oligopeptidesAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- Local irritationDermatologicUnknown
- Gastrointestinal toxicityGastrointestinalUnknown
- MyelosuppressionHematologicUnknown
- NephrotoxicityRenalUnknown
Drug Interactions
- Alkylating agentsModerate
- Other DNA-intercalating or groove-binding agentsHigh
Population Constraints
- Pediatric populationsAgeRelative
- Patients with pre-existing bone marrow suppressionHematologicRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionUnapprovedNot approved by EMA; research/investigational use only.
- United StatesUnapprovedResearch use only; not FDA-approved for any indication.
- United KingdomUnapprovedNot approved by MHRA; used only in research contexts.
Not approved by any major regulatory authority (FDA, EMA, MHRA) for clinical use. Used exclusively as a research tool compound and as a pharmacophore template for drug design.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Stallimycin?
Stallimycin (distamycin A) is a naturally occurring oligopeptide antibiotic produced by Streptomyces distallicus. It binds non-covalently to the minor groove of B-form DNA at AT-rich regions, inhibiting RNA and DNA synthesis. It has demonstrated antiviral, antibacterial, and antitumor activities in vitro and in vivo, but has not progressed to clinical approval due to toxicity concerns. It served as the parent scaffold for numerous synthetic analogues (lexitropsins, tallimustine) developed in cancer and antiviral research.
What is Stallimycin used for?
Stallimycin is educationally associated with: Antitumor activity, Antiviral activity, Research tool for DNA-binding studies, Antibacterial activity. Educational only — not medical advice.
How is Stallimycin administered?
Recorded routes of administration: Intravenous, Topical.
What are the potential side effects of Stallimycin?
Reported adverse effects include: Local irritation, Gastrointestinal toxicity, Myelosuppression, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Stallimycin?
Recorded contraindications: Known hypersensitivity to distamycin or related oligopeptides, Pregnancy. Consult a qualified clinician before use.